PsychonautWiki Archive

2C-D: Difference between revisions

← Older edit
>David Hedlund
https, and no www.
>Dutchmonster
m Add legality + citation for Netherlands, with a focus on a recent law that is a blanket ban
 
(25 intermediate revisions by 11 users not shown)
Line 2: Line 2:
{{SubstanceBox/2C-D}}
{{SubstanceBox/2C-D}}


'''2,5-Dimethoxy-4-methylphenethylamine''' (also known as '''2C-M''' and more commonly as '''2C-D''') is a synthetic [[Psychoactive class::psychedelic]] of the [[Chemical class::phenethylamine]] chemical class that produces short-lived [[psychedelic]] effects when [[routes of administration|administered]]. Its sensory and cognitive effects profile has been described as being the most similar to that of [[mescaline]] among members of the [[2C-x family]], albeit with a significantly shorter duration.
'''2,5-Dimethoxy-4-methylphenethylamine''' (also known as '''2C-M''', '''LE-25''' and more commonly as '''2C-D''') is a synthetic [[Psychoactive class::psychedelic]] of the [[Chemical class::phenethylamine]] chemical class that produces short-lived [[psychedelic]] effects when [[routes of administration|administered]]. Its sensory and cognitive effects profile has been described as being the most similar to that of [[mescaline]] among members of the [[2C-x family]], albeit with a significantly shorter duration.


The synthesis of 2C-D was first published in 1970 by a team from the Texas Research Institute of Mental Sciences.<ref>Amphetamine analogs. II. Methylated phenethylamines (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/5412084</ref> Initial trials by [[Alexander Shulgin]] at sub-threshold doses in humans were carried out in 1964.<ref>Shulgin, Alexander. "Pharmacology Lab Notes #1". Lafayette, CA. (1960-1976). p94, p175 (Erowid.org) | https://erowid.org/library/books_online/shulgin_labbooks/shulgin_labbook1_searchable.pdf</ref>
The synthesis of 2C-D was first published in 1970 by a team from the Texas Research Institute of Mental Sciences.<ref name="Ho1970">{{cite journal|title=Amphetamine analogs. II. Methylated phenethylamines|pmid=5412084|doi=10.1021/jm00295a034|year=1970|volume=13|issue=1|pages=134-135|first1=B. T.|last1=Ho|first2=L. W.|last2=Tansey|first3=R. L.|last3=Balster|first4=R.|last4=An|first5=W. M.|last5=McIsaac|first6=R. T.|last6=Harris|journal=Journal of Medicinal Chemistry|issn=0022-2623|eissn=1520-4804|oclc=39480771}}</ref> Initial trials by [[Alexander Shulgin]] at sub-threshold doses in humans were carried out in 1964.<ref name="Shulgin1976">{{cite book|author=Alexander Shulgin|author-link=Alexander Shulgin|title=Pharmacology Notes I (The Shulgin Lab Books)|publisher=Erowid|url=https://erowid.org/library/books_online/shulgin_labbooks/shulgin_labbook1_searchable.pdf|page=176|place=Lafayette, CA|year=1976}}</ref>
 
In his book [[PiHKAL]] ("Phenethylamines I Have Known And Loved"), Shulgin lists the dosage range as being from 20 to 60 mg. This is now regarded by some as a conservative estimate as it has since been reported that substantially higher doses are capable of inducing a full spectrum of classical psychedelic effects while remaining physically unthreatening, a relatively unique quality in the [[2C-x family]].


Many anecdotal reports suggest that it is calmer, easier to handle and more comfortable on the body than other closely related [[psychedelic]] [[phenethylamines]]. While not especially visual or physically euphoric at common doses, it is reported to be very lucid, analytical and unimpaired in its headspace - a quality it retains even as the dose is increased.
Many anecdotal reports suggest that it is calmer, easier to handle and more comfortable on the body than other closely related [[psychedelic]] [[phenethylamines]]. While not especially visual or physically euphoric at common doses, it is reported to be very lucid, analytical and unimpaired in its headspace - a quality it retains even as the dose is increased.


Lower doses of 2C-D (generally 10 mg or less) have been explored for its use as a potential [[nootropic]], albeit with mixed results.<ref>Lemaire, D. (1990). Erowid 2C-D Vault: Smart Pills, by Hosten & Lazar. Retrieved from https://www.erowid.org/chemicals/2cd/2cd_smartpills1.shtml</ref>
Lower doses of 2C-D (generally 10 mg or less) have been explored for its use as a potential [[nootropic]], albeit with mixed results.<ref>{{cite web|author=Darrell Lemaire|year=1990|orig-year=Updated 2015|publisher=Erowid|url=https://www.erowid.org/chemicals/2cd/2cd_smartpills1.shtml|title=Certain Exotic Transmitters as Smart Pills or Compounds that Increase the Capacity for Mental Work in Humans|access-date=October 11, 2020}}</ref>


Today, 2C-D is used both recreationally and as an [[entheogen]]. It is rarely sold on the streets and almost exclusively distributed as a gray area [[research chemical]] by online vendors.  
Today, 2C-D is used both recreationally and as an [[entheogen]]. It is rarely sold on the streets and almost exclusively distributed as a gray area [[research chemical]] by online vendors.  


==History and culture==
==History and culture==
The synthesis of 2C-D was first published in 1970 by a team from the Texas Research Institute of Mental Sciences,<ref>Amphetamine analogs. II. Methylated phenethylamines (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/5412084</ref>, but initial trials by [[Alexander Shulgin]] at sub-threshold doses were carried out in 1964. Further investigations at higher doses were carried out by Shulgin and his fellow researchers between 1974 and 1978.<ref>Shulgin, Alexander. "Pharmacology Lab Notes #1". Lafayette, CA. (1960-1976). p94, p175 (Erowid.org) | https://erowid.org/library/books_online/shulgin_labbooks/shulgin_labbook1_searchable.pdf</ref> The name '2C-D' derives from the chemical's structure - it is the 2-Carbon analogue of [[DOM]].
The synthesis of 2C-D was first published in 1970 by a team from the Texas Research Institute of Mental Sciences,<ref name="Ho1970"/>, but initial trials by [[Alexander Shulgin]] at sub-threshold doses were carried out in 1964. Further investigations at higher doses were carried out by Shulgin and his fellow researchers between 1974 and 1978.<ref name="Shulgin1976"/> The name '2C-D' derives from the chemical's structure - it is the 2-Carbon analogue of [[DOM]].


Notably, Shulgin referred to 2C-D as a “pharmacological tofu,” meaning it can extend or potentiate the effect of other substances without overly coloring the experience, in a manner similar to how tofu absorbs the flavors of sauces or spices it is cooked with.{{citation needed}} While some use this as evidence that 2C-D is relatively uninteresting as a psychedelic on its own, others strongly disagree with this assessment and hold that 2C-D is an unusually versatile and fully-fledged [[psychedelic]] in its own right.  
Shulgin notably referred to 2C-D as a “pharmacological tofu,” meaning it can extend or potentiate the effect of other substances without overly coloring the experience, in a manner similar to how tofu absorbs the flavors of sauces or spices it is cooked with.{{citation needed}} While some use this as evidence that 2C-D is relatively uninteresting as a psychedelic on its own, others strongly disagree with this assessment and hold that 2C-D is an unusually versatile and fully-fledged [[psychedelic]] in its own right.  
 
Despite showing promise as a very functional psychostimulant<ref>{{cite journal|last1=Zuba|first1=D.|last2=Sekuła|first2=K.|year=2013|title=Analytical characterization of three hallucinogenic N-(2-methoxy)benzyl derivatives of the 2C-series of phenethylamine drugs|journal=Drug Testing and Analysis|volume=5|issue=8|pages=634–645|doi=10.1002/dta.1397|pmid=22936468|issn=1942-7603|eissn=1942-7611|oclc=231680670}}</ref><ref>{{cite journal|last1=King|first1=L. A.|year=2014|title=New phenethylamines in Europe|journal=Drug Testing and Analysis|volume=6|issue=7–8|pages=808–818|doi=10.1002/dta.1570|pmid=24574327|issn=1942-7603|eissn=1942-7611|oclc=231680670}}</ref> with successful studies investigating the use in psychotherapy in Germany,<ref>{{cite book|last1=Schneider|first1=U.|first2=D.E.|last2=Dietrich|first3=U.|last3=Gast|year=2004|title=Aspekte des Psychischen: Festschrift anlässlich des 60. Geburtstags von Hinderk M. Emrich|location=Würzbug, Germany|publisher=Königshausen & Neumann|language=de|isbn=3826027299|oclc=55887990}}</ref> 2C-D has not found widespread use. This has been argued to be due to the previously limited diversity of substances on the market - a consumer dynamic which has changed significantly with the advent of the internet - allowing a broader freedom of choice for explorers of psychedelic phenethylamines.<ref>{{cite book|author=James Martin|year=2014|doi=10.1057/9781137399052|title=Drugs on the Dark Net: How Cryptomarkets are Transforming the Global Trade in Illicit Drugs|isbn=978-1-349-48566-6|oclc=903145880|publisher=Palgrave Macmillan|location=Basingstoke, UK|series=Palgrave pivot.}}</ref> Of these, it tends to be substantially harder to find and notably more expensive by weight.{{citation needed}}


Despite showing promise as a very functional psychostimulant<ref>Zuba, D., & Sekula, K. (2013). Analytical characterization of three hallucinogenic N-(2-methoxy)benzyl derivatives of the 2C-series of phenethylamine drugs. Drug Testing and Analysis, 5(8), 634–645. https://doi.org/10.1002/dta.1397</ref><ref>King, L. A. (2014). New phenethylamines in Europe. Drug Testing and Analysis, 6(7–8), 808–818. https://doi.org/10.1002/dta.1570</ref> with successful studies investigating the use in psychotherapy in Germany,<ref>Schneider, U. (2004). Aspekte des Psychischen: Festschrift anlässlich des 60. Geburtstags von Hinderk M. Emrich. Würzbug, Germany: Königshausen & Neumann. '''No complete fulltext was available at the time of writing, please refer to the Google Scholar document: https://books.google.de/books?id=yo45tYQj2-MC&lpg=PA129&ots=tW1EqmhrGF&dq=DMM-PEA&hl=de&pg=PA129&output=embed.'''</ref> 2C-D has not found widespread use. This has been argued to be due to the previously limited diversity of substances on the market - a consumer dynamic which has changed significantly with the advent of the internet - allowing a broader freedom of choice for explorers of psychedelic phenethylamines.<ref>Martin, J. (2014). Drugs on the Dark Net. London: Palgrave Macmillan UK. https://doi.org/10.1057/9781137399052</ref> Of these, it tends to be substantially harder to find and notably more expensive by weight.{{citation needed}}
==Chemistry==
==Chemistry==
[[File:Phenethylamine.png|thumb|right|253px|thumb|right|253px||Generic structure of a phenethylamine molecule]]
[[File:Phenethylamine.png|thumb|right|253px|thumb|right||Generic structure of a phenethylamine molecule]]
2C-D, or 2,5-dimethoxy-4-methylphenethylamine, is a substituted [[phenethylamines|phenethylamine]] featuring a phenyl ring bound to an amino (NH<sub>2</sub>) group through an ethyl chain. 2C-D contains methoxy functional groups CH<sub>3</sub>O- attached to carbons R<sub>2</sub> and R<sub>5</sub> as well as a methyl group attached to carbon R<sub>4</sub> of the phenyl ring.  
2C-D, or 2,5-dimethoxy-4-methylphenethylamine, is a substituted [[phenethylamines|phenethylamine]] featuring a phenyl ring bound to an amino (NH<sub>2</sub>) group through an ethyl chain. 2C-D contains methoxy functional groups CH<sub>3</sub>O- attached to carbons R<sub>2</sub> and R<sub>5</sub> as well as a methyl group attached to carbon R<sub>4</sub> of the phenyl ring.  


Line 31: Line 30:


==Subjective effects==
==Subjective effects==
The head space of 2C-D is described by many as being lucid, insightful and relatively normal in its thought processes even at moderate to high doses. The feeling of unaltered consciousness may be unsatisfying to users who want an intense experience because the head space is fairly normal, stable and therefore sometimes uninteresting to those who are new to hallucinogenic experiences.
{{Preamble/SubjectiveEffects}}
{{Preamble/SubjectiveEffects}}
{{effects/base
{{effects/base
Line 64: Line 65:


====[[effect::Geometry]]====
====[[effect::Geometry]]====
The visual geometry that is able to be produced by this substance can be described as more similar in appearance to that of [[DOM]] or [[25D-NBOMe]] than that of [[LSD]], [[2C-B]] or [[2C-I]]. It can be comprehensively described as structured in its organization, organic in style, intricate in complexity, large in style, slow and smooth in motion, colorful in scheme, bright in color, blurred in its edges and equally rounded and angular in its corners. It gives off a natural feel at higher dosages. While the final level of 2C-D geometry has yet to be formally confirmed, it seems more likely that it would result in states of [[Effect::8B Geometry|level 8B]] visual geometry over [[8A Geometry|level 8A]].
The visual geometry of 2C-D be described as more similar in appearance to that of [[DOM]] or [[25D-NBOMe]] than that of [[LSD]], [[2C-B]] or [[2C-I]]. It can be comprehensively described as structured in its organization, organic in style, intricate in complexity, large in style, slow and smooth in motion, colorful in scheme, bright in color, blurred in its edges and equally rounded and angular in its corners. It gives off a natural feel at higher dosages. While the final level of 2C-D geometry has yet to be formally confirmed, it seems more likely that it would result in states of [[Effect::8B Geometry|level 8B]] visual geometry over [[8A Geometry|level 8A]].


====Hallucinatory states====
====Hallucinatory states====
*'''[[Effect::Transformations]]'''
*'''[[Effect::Transformations]]'''
*'''[[Effect::Internal hallucinations]]''' (''[[effect::autonomous entities]]''; ''[[effect::settings, sceneries, and landscapes]]''; ''[[effect::alterations in perspective]]'' and ''[[effect::scenarios and plots]]'') - In comparison to other psychedelics such as [[LSD]], 2C-D is low in hallucinations embedded within visual geometry. However, when it does occur this particular effect commonly contains hallucinations with scenarios, settings, concepts and autonomous entity contact. They are more common within dark environments and can be described as internal in their manifestation, lucid in believability, and interactive in style.
*'''[[Effect::Internal hallucination]]''' (''[[effect::autonomous entities]]''; ''[[effect::settings, sceneries, and landscapes]]''; ''[[effect::perspective hallucinations]]'' and ''[[effect::scenarios and plots]]'') - In comparison to other psychedelics such as [[LSD]], 2C-D is low in hallucinations embedded within visual geometry. However, when it does occur this particular effect commonly contains hallucinations with scenarios, settings, concepts and autonomous entity contact. They are more common within dark environments and can be described as internal in their manifestation, lucid in believability, and interactive in style.
*'''[[Effect::External hallucinations]]''' (''[[effect::settings, sceneries, and landscapes]]''; ''[[effect::alterations in perspective]]'' and ''[[effect::scenarios and plots]]'') -  2C-D is capable of external hallucinations embedded within visual geometry. This particular effect commonly contains hallucinations with scenarios, settings, concepts and autonomous entity contact. They can be described as external in their manifestation, lucid in believability, and fixed in style.
*'''[[Effect::External hallucination]]''' (''[[effect::settings, sceneries, and landscapes]]''; ''[[effect::perspective hallucinations]]'' and ''[[effect::scenarios and plots]]'') -  2C-D is capable of external hallucinations embedded within visual geometry. This particular effect commonly contains hallucinations with scenarios, settings, concepts and autonomous entity contact. They can be described as external in their manifestation, lucid in believability, and fixed in style.


}}
}}
|{{effects/cognitive|
|{{effects/cognitive|
The head space of 2C-D is described by many as being lucid, insightful and relatively normal in its thought processes even at moderate to high doses. The feeling of unaltered consciousness may be unsatisfying to users who want an intense experience because the head space is fairly normal, stable and therefore sometimes uninteresting to those who are new to hallucinogenic experiences.
 
*'''[[Effect::Analysis enhancement]]'''
*'''[[Effect::Analysis enhancement]]'''
*'''[[Effect::Conceptual thinking]]'''
*'''[[Effect::Conceptual thinking]]'''
Line 109: Line 110:
===Experience reports===
===Experience reports===
There are currently no anecdotal reports which describe the effects of this compound within our [[experience index]]. Additional experience reports can be found here:
There are currently no anecdotal reports which describe the effects of this compound within our [[experience index]]. Additional experience reports can be found here:
* [https://erowid.org/experiences/subs/exp_2CD.shtml Erowid Experience Vaults: 2C-D]
 
*[https://erowid.org/experiences/subs/exp_2CD.shtml Erowid Experience Vaults: 2C-D]


==Toxicity and harm potential==
==Toxicity and harm potential==
Line 125: Line 127:
===Dangerous interactions===
===Dangerous interactions===
{{DangerousInteractions/Intro}}
{{DangerousInteractions/Intro}}
{{DangerousInteractions/Psychedelics}}


*'''[[Tramadol]]''' - Tramadol lowers the seizure threshold<ref>Talaie, H., Panahandeh, R., Fayaznouri, M. R., Asadi, Z., & Abdollahi, M. (2009). Dose-independent occurrence of seizure with tramadol. Journal of medical toxicology, 5(2), 63-67. doi:10.1007/BF03161089</ref> and [[psychedelics]] may act as triggers for seizures, particularly in those who are predisposed to them.{{citation needed}}
==Legal status==
*'''[[Stimulants]]''' - Stimulants affect many parts of the brain. Combined with psychedelics, stimulation can turn into uncontrollable [[anxiety]], [[Panic attacks|panic]], [[thought loops]] and [[paranoia]]. This interaction may cause elevated risk of psychosis.{{citation needed}}
*'''[https://en.wikipedia.org/wiki/Lithium_(medication) Lithium]''' - Lithium is often used as treatment for bipolar disorder. It may possibly cause elevated risk of seizures and psychosis due to its [[Glutamate|glutaminergic]] and [[GABA|GABAergic]] effects.{{citation needed}}


==Legality==
*'''Australia''': Australia has a blanket ban over all substituted phenethylamines including the entire 2C-X family.<ref>{{cite web|title=Psychoactive Substances|publisher=National Drug and Alcohol Research Centre|year=2014|url=https://comorbidity.edu.au/sites/default/files/cre/page/New%20Psychoactive%20Substances.pdf}}{{dead link|date=October 2020}}</ref>
*'''Australia:''' Australia has a blanket ban over all substituted phenethylamines including the entire 2C-X family.<ref>New Psychoactive Substances (National Drug and Alcohol Research Centre 2014) | https://comorbidity.edu.au/sites/default/files/cre/page/New%20Psychoactive%20Substances.pdf</ref>
*'''Austria''': 2C-D is illegal to possess, produce and sell under the NPSG (Neue-Psychoaktive-Substanzen-Gesetz Österreich). In its Schedule II, the further specifying NPSV (Neue-Psychoaktive-Substanzen-Verordnung Österreich) explicitly bans all substituted phenetylamines.<ref>{{cite web|url=https://www.ris.bka.gv.at/GeltendeFassung.wxe?Abfrage=Bundesnormen&Gesetzesnummer=20007642|title=Bundesrecht konsolidiert: Gesamte Rechtsvorschrift für Neue-Psychoaktive-Substanzen-Verordnung|date=June 26, 2019|language=de|access-date=January 10, 2021}}</ref>
*'''Brazil''' - Possession, production and sale is illegal as it is listed on Portaria SVS/MS nº 344.<ref>http://portal.anvisa.gov.br/documents/10181/3115436/%281%29RDC_130_2016_.pdf/fc7ea407-3ff5-4fc1-bcfe-2f37504d28b7</ref>
*'''Brazil''': Possession, production and sale is illegal as it is listed on Portaria SVS/MS nº 344.<ref>{{cite web|url=http://portal.anvisa.gov.br/documents/10181/3115436/%281%29RDC_130_2016_.pdf/fc7ea407-3ff5-4fc1-bcfe-2f37504d28b7|title=RESOLUÇÃO DA DIRETORIA COLEGIADA - RDC N° 130, DE 2 DE DEZEMBRO DE 2016|publication-date=December 5, 2016|publisher=Agência Nacional de Vigilância Sanitária (ANVISA) [Brazilian Health Regulatory Agency (ANVISA)]|language=pt}}</ref>
*'''Canada:''' 2C-D would be considered Schedule III as it is a derivative of 2,5-dimethoxyphenethylamine.<ref>Controlled Drugs and Substances Act (S.C. 1996, c. 19) |http://laws-lois.justice.gc.ca/eng/acts/C-38.8/page-12.html#h-28</ref>
*'''Canada''': 2C-D would be considered Schedule III as it is a derivative of 2,5-dimethoxyphenethylamine.<ref>{{cite web|url=http://isomerdesign.com/Cdsa/schedule.php?schedule=3&section=ALL&structure=C|title=Schedule III|work=Controlled Drugs and Substances Act (CDSA)|publisher=Isomer Design|access-date=October 10, 2020}}</ref>
*'''China''' - As of October 2015 2C-D is a controlled substance in China.<ref>{{cite web | url=http://www.sfda.gov.cn/WS01/CL0056/130753.html | title=关于印发《非药用类麻醉药品和精神药品列管办法》的通知 | publisher=China Food and Drug Administration | date=27 September 2015 | language=Chinese | accessdate=1 October 2015}}</ref>
*'''China''': 2C-D is a controlled substance in China as of October 2015.<ref>{{cite web|url=http://www.sfda.gov.cn/WS01/CL0056/130753.html|title=关于印发《非药用类麻醉药品和精神药品列管办法》的通知|publisher=国家食品药品监督管理总局 [China Food and Drug Administration (CFDA)]|date=September 27, 2015|language=zh|archive-url=https://web.archive.org/web/20170906191704/http://www.sfda.gov.cn/WS01/CL0056/130753.html|archive-date=September 6, 2017}}</ref>
*'''Denmark''': 2C-D is added to the list of Schedule B controlled substances.<ref>Bekendtgørelse om euforiserende stoffer | https://www.retsinformation.dk/Forms/R0710.aspx?id=137169</ref>
*'''Denmark''': 2C-D is added to the list of Schedule B controlled substances.<ref>{{cite web|url=https://www.retsinformation.dk/Forms/R0710.aspx?id=137169|title=Bekendtgørelse om euforiserende stoffer|access-date=December 10, 2019|language=da|id=BEK Nr. 557|date=May 31, 2011|publisher=Civilstyrelsen [Civil Agency]}}</ref>
*'''Germany''': On December 13, 2014, 2C-D was added to the controlled substance act ("BtMG"), making it illegal to produce, sell or possess.<ref>Achtundzwanzigste Verordnung zur Änderung betäubungsmittelrechtlicher Vorschriften (28. BtMÄndV)| http://www.buzer.de/gesetz/11392/a189949.htm</ref>
*'''Germany''': 2C-D is controlled under Anlage I BtMG (''Narcotics Act, Schedule I'')<ref>{{cite web|url=https://www.gesetze-im-internet.de/btmg_1981/anlage_i.html|title=Gesetz über den Verkehr mit Betäubungsmitteln: Anlage I|publisher=Bundesamt für Justiz [Federal Office of Justice]|access-date=December 10, 2019|language=de}}</ref> as of December 13, 2014.<ref>{{cite web|url=http://www.bgbl.de/xaver/bgbl/start.xav?startbk=Bundesanzeiger_BGBl&jumpTo=bgbl114s1999.pdf|title=Achtundzwanzigste Verordnung zur Änderung betäubungsmittelrechtlicher Vorschriften|publisher=Bundesanzeiger Verlag|work=Bundesgesetzblatt Jahrgang 2014 Teil I Nr. 57|page=1999-2002|publication-date=December 12, 2014|language=de|oclc=231871244|issn=0341-1095|date=December 5, 2014}}</ref> It is illegal to manufacture, possess, import, export, buy, sell, procure or dispense it without a license.<ref>{{cite web|url=https://www.gesetze-im-internet.de/btmg_1981/__29.html|title=Gesetz über den Verkehr mit Betäubungsmitteln: § 29|publisher=Bundesamt für Justiz [Federal Office of Justice]|access-date=December 10, 2019|language=de}}</ref>
*'''Japan:''' 2C-D is controlled by the Pharmaceutical Affairs Law in Japan, making it illegal to possess or sell.<ref>Analytical Data of Designated Substances (Shitei-Yakubutsu) Controlled by the Pharmaceutical AŠairs Law in Japan, Part I: GC-MS and LC-MS | https://www.erowid.org/references/texts/show/7395docid7635</ref>
*'''Japan''': 2C-D is controlled by the Pharmaceutical Affairs Law in Japan, making it illegal to possess or sell.<ref>{{cite journal|title=Analytical Data of Designated Substances (Shitei-Yakubutsu) Controlled by the Pharmaceutical Affairs Law in Japan, Part I: GC-MS and LC-MS|url=https://www.erowid.org/references/texts/show/7395docid7635|language=ja|volume=128|issue=6|pages=971-979|journal=Yakugaku Zasshi|eissn=0031-6903|issn=1347-5231|oclc=909890652|year=2008|pmid=18520145|doi=10.1248/yakushi.128.981|first1=N.|last1=Uchiyama|first2=M.|last2=Kawamura|first3=H.|last3=Kamakura|first4=R.|last4=Kikura-Hanajiri|first5=Y.|last5=Goda}}</ref>
*'''Latvia:''' 2C-D is a Schedule I controlled substance.<ref>Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem (2,5-Dimetoksifeniletānamīni) | http://likumi.lv/doc.php?id=121086</ref>
*'''Latvia''': 2C-D is a Schedule I controlled substance.<ref>{{cite web|url=http://likumi.lv/doc.php?id=121086|title=Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem|publisher=VSIA Latvijas Vēstnesis|access-date=January 1, 2020|publication-date=November 10, 2005|language=lv}}</ref>
*'''Switzerland:''' Possession, production and sale is illegal.<ref>http://web.archive.org/web/20170329020935/https://www.admin.ch/opc/de/classified-compilation/20101220/index.html</ref>
*'''The Netherlands:''' 2C-D is currently legal, but it is part of a substance group that may be banned soon as part of a recently passed law on New Psychoactive Substances (NPS). <ref>{{Citation|title= Wijziging van de Opiumwet in verband met het toevoegen van een derde lijst met als doel het tegengaan van de productie van en de handel in nieuwe psychoactieve stoffen en enkele andere wijzigingen (Dutch) | year=2024|url=https://www.tweedekamer.nl/kamerstukken/wetsvoorstellen/detail?id=2022Z14042&dossier=36159}}</ref>  
*'''Sweden:''' 2C-D is classified as a health hazard as of March 1, 2005, in the regulation SFS 2005:26, making it illegal to sell or possess.<ref>Svensk författningssamling | http://www.notisum.se/rnp/sls/sfs/20050026.pdf</ref>
*'''Sweden''': 2C-D is classified as a health hazard as of March 1, 2005, in the regulation SFS 2005:26, making it illegal to sell or possess.<ref>{{cite web|title=Svensk författningssamling Förordning om ändring i förordningen (1999:58) om förbud mot vissa hälsofarliga varor|url=http://www.notisum.se/rnp/sls/sfs/20050026.pdf|id=SFS 2005:26|language=sv|date=February 3, 2005|publication-date=February 15, 2005|publisher=Läkemedelsverket [Swedish Medical Products Agency]|issn=1101-5225|work=Läkemedelsverkets författningssamling (LVFS)}}</ref>
*'''United Kingdom:''' 2C-D is a Class A controlled substance as it is covered by the phenethylamine derivatives clause of the Misuse of Drugs Act of 1971.{{citation needed}}
*'''Switzerland''': 2C-D is a controlled substance specifically named under Verzeichnis E.<ref>{{cite web|url=https://www.admin.ch/opc/de/classified-compilation/20101220/index.html|title=Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien|publisher=Bundeskanzlei [Federal Chancellery of Switzerland]|access-date=January 1, 2020|language=de}}</ref>
*'''United States:''' 2C-D is listed in Schedule I of section 202(c) of the Controlled Substances Act in the United States. This was signed into law as of July 2012 under the Food and Drug Administration Safety and Innovation Act.<ref>S. 3187: Food and Drug Administration Safety and Innovation Act, Subtitle D-Synthetic Drugs | http://www.govtrack.us/congress/bills/112/s3187/text</ref>
*'''Turkey:''' 2C-D is a classed as drug and is illegal to possess, produce, supply, or import.<ref>Bakanlar Kurulu Kararı Karar Sayısı : 2013/4827 | https://free-ankara.org/wp-content/uploads/2017/09/BKK_2013_4827_28688.pdf</ref>
*'''United Kingdom''': 2C-D is a Class A drug in the United Kingdom as a result of the phenethylamine catch-all clause.<ref>{{cite web|title=Schedule 2: Part I: Class A Drugs|url=http://www.legislation.gov.uk/ukpga/1971/38/schedule/2/part/I|work="Misuse of Drugs Act 1971"|access-date=August 20, 2020|publisher=UK Government}}</ref>
*'''United States''': 2C-D is listed in Schedule I of section 202(c) of the Controlled Substances Act in the United States. This was signed into law as of July 2012 under the Food and Drug Administration Safety and Innovation Act.<ref>{{cite web|url=http://www.govtrack.us/congress/bills/112/s3187/text|title=S. 3187 (112<sup>th</sup>): Food and Drug Administration Safety and Innovation Act|date=June 27, 2012|access-date=October 10, 2020|publisher=GovTrack}}</ref>


==See also==
==See also==
*[[Responsible use]]
*[[Responsible use]]
*[[Psychoactive substance index]]
*[[Psychoactive substance index]]
Line 153: Line 157:


==External links==
==External links==
*[https://en.wikipedia.org/wiki/2C-D 2C-D (Wikipedia)]
*[https://en.wikipedia.org/wiki/2C-D 2C-D (Wikipedia)]
*[https://erowid.org/chemicals/2cd/2cd.shtml 2C-D (Erowid Vault)]
*[https://erowid.org/chemicals/2cd/2cd.shtml 2C-D (Erowid Vault)]
*[https://isomerdesign.com/PiHKAL/read.php?id=23 2C-D (PiHKAL / Isomer Design)]
*[https://isomerdesign.com/PiHKAL/read.php?domain=pk&id=23 2C-D (PiHKAL / Isomer Design)]


===Forums===
===Forums===
*[http://www.bluelight.org/vb/threads/111481-The-Big-amp-Dandy-2C-D-Thread 2C-D (Bluelight)]
*[http://www.bluelight.org/vb/threads/111481-The-Big-amp-Dandy-2C-D-Thread 2C-D (Bluelight)]


Line 163: Line 169:
{{reflist|2}}
{{reflist|2}}
{{#set:Featured=true}}
{{#set:Featured=true}}
[[Category:Psychoactive substance]]
[[Category:Psychoactive substance]]
[[Category:Phenethylamine]]
[[Category:Psychedelic]]
[[Category:Psychedelic]]
[[Category:2C-x]]
Retrieved from "http://psy.st/wiki/2C-D"